Daewoong Pharmaceutical to export botox to U.S., Europe
Sept 30, 2013
Daewoong Pharmaceutical Co., a major South Korean drug maker, said Monday it has signed a deal with Evolus, a U.S. biotech venture, in a bid to sell its Botox products in the U.S. and European markets beginning as early as 2016.The deal is designed to start regulatory processes for approval of botulinum toxin type A in the U.S. and European markets, according to Daewoong.Daewoong said it will export botulinum toxin type A, which will be marketed as Nabota, while Evolus will be in charge of clini